Novo Nordisk Withdrawal to Reshape Insulin Market; Lupin's Huminsulin to Gain Spotlight Farhat Nasim24 April 2025 6:29 PM ISTMumbai: Amidst the ongoing news of conventional insulin market disruption and growing concern over potential shortages triggered by Novo...
Conduct BE study or present safety data: CDSCO Panel tells IQVIA on anti-cancer Drug Daratumumab study Dr. Divya Colin15 March 2025 5:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined IQVIA to conduct the...
Indian Pharma Market Expands 8.4% in January, Dapagliflozin, Vonoprazan Among Top-Selling Drugs: IQVIA Farhat Nasim24 Feb 2025 5:12 PM ISTVonoprazan-based GI drugs led new launches, generating Rs 187 crore from 404 brands.
IQVIA Gets CDSCO Panel Nod To conduct Phase III clinical Study of Lumateperone Dr. Divya Colin28 Dec 2024 6:30 PM ISTNew Delhi: IQVIA has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to...
Indian Pharma Market Posts Robust 10.7% Growth in November, Foracort Tops Sales: IQVIA Farhat Nasim14 Dec 2024 5:52 PM ISTLeading the market, Foracort, a respiratory drug widely used for asthma, secured the top position among brands with sales of Rs 82 crore.
IQVIA Gets CDSCO Panel Nod to Study Antipsychotic drug Lumateperone Dr. Divya Colin17 Nov 2024 5:45 PM ISTNew Delhi: IQVIA has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to...
Submit preclinical data in animal and Phase I CT data: CDSCO Panel Tells IQVIA on Pembrolizumab study Dr. Divya Colin2 Nov 2024 6:00 PM ISTNew Delhi: After reviewing the Phase I/III clinical study protocol of the anti-cancer drug Pembrolizumab, the Subject Expert Committee (SEC)...
IQVIA Gets CDSCO Panel Nod to Study KarXT in Schizophrenia Dr. Divya Colin31 Oct 2024 5:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to IQVIA...
CDSCO Panel Approves IQVIA RDS Protocol Amendment Proposal for Survodutide study Dr. Divya Colin2 Oct 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
CDSCO Panel Approves IQVIA RDS's Protocol Amendment Proposal for Spesolimab study Dr. Divya Colin11 Aug 2024 5:15 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved IQVIA RDS's...
Atleast 50% more geographically distributed Govt sites be included: CDSCO panel Tells IQVIA in Milvexian study Dr. Divya Colin3 April 2024 6:00 PM ISTNew Delhi: Reviewing the proposal presented by IQVIA regarding the waiving of the specific condition in the Milvexian study, the Subject Expert...
CDSCO Panel Approves IQVIA's Protocol Amendment Proposal For Anti-cancer Drug Xevinapant Dr. Divya Colin27 March 2024 5:30 AM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
